Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 973406, 7 pages
http://dx.doi.org/10.1155/2014/973406
Research Article

Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer

1Department of Urology, Eberhard-Karls University, Hoppe-Seyler Strasse 3, 72076 Tübingen, Germany
2Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z6

Received 11 September 2014; Accepted 5 December 2014; Published 22 December 2014

Academic Editor: Marco E. M. Peluso

Copyright © 2014 Tilman Todenhöfer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Xylinas, M. Kent, L. Kluth et al., “Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder,” British Journal of Cancer, vol. 109, no. 6, pp. 1460–1466, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Witjes, E. Compérat, N. C. Cowan et al., “EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines,” European Urology, vol. 65, no. 4, pp. 778–792, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. B. W. G. van Rhijn, M. Burger, Y. Lotan et al., “Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy,” European Urology, vol. 56, no. 3, pp. 430–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Schrag, L. J. Hsieh, F. Rabbani, P. B. Bach, H. Herr, and C. B. Begg, “Adherence to surveillance among patients with superficial bladder cancer,” Journal of the National Cancer Institute, vol. 95, no. 8, pp. 588–597, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. H. B. Grossman, M. Soloway, E. Messing et al., “Surveillance for recurrent bladder cancer using a point-of-care proteomic assay,” The Journal of the American Medical Association, vol. 295, no. 3, pp. 299–305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Mian, K. Maier, E. Comploj et al., “uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma,” Cancer, vol. 108, no. 1, pp. 60–65, 2006. View at Publisher · View at Google Scholar
  7. P. S. Sullivan, F. Nooraie, H. Sanchez et al., “Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a “split-sample” study,” Cancer Cytopathology, vol. 117, no. 3, pp. 167–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Kamat, P. K. Hegarty, J. R. Gee et al., “ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers,” European Urology, vol. 63, no. 1, pp. 4–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. B. J. Schmitz-Drager, T. Todenhofer, B. van Rhijn et al., “Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer,” Urologic Oncology, vol. 32, no. 7, pp. 1061–1068, 2014. View at Publisher · View at Google Scholar
  10. T. Todenhöfer, J. Hennenlotter, V. Tews et al., “Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 7, pp. 1148–1154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. L. J. Layfield, T. M. Elsheikh, A. Fili, R. Nayar, and V. Shidham, “Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting: the Papanicolaou Society of Cytopathology Practice Guidelines Task Force,” Diagnostic Cytopathology, vol. 30, no. 1, pp. 24–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Riesz, G. Lotz, C. Páska et al., “Detection of bladder cancer from the urine using fluorescence in situ hybridization technique,” Pathology & Oncology Research, vol. 13, no. 3, pp. 187–194, 2007. View at Publisher · View at Google Scholar
  13. I. A. Sokolova, K. C. Halling, R. B. Jenkins et al., “The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in Urine,” Journal of Molecular Diagnostics, vol. 2, no. 3, pp. 116–123, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Mian, A. Pycha, H. Wiener, A. Haitel, M. Lodde, and M. Marberger, “Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract,” The Journal of Urology, vol. 161, no. 5, pp. 1486–1489, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. K. L. Greene, A. Berry, and B. R. Konety, “Diagnostic utility of the immunoCyt/uCyt+ test in bladder cancer,” Reviews in Urology, vol. 8, pp. 190–197, 2006. View at Google Scholar
  16. S. F. Shariat, M. J. Marberger, Y. Lotan et al., “Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer,” Journal of Urology, vol. 176, no. 3, pp. 919–926, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Soukup, M. Babjuk, J. Bellmunt et al., “Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature,” European Urology, vol. 62, no. 2, pp. 290–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Witjes, J. P. Redorta, D. Jacqmin et al., “Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations,” European Urology, vol. 57, no. 4, pp. 607–614, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Palou Redorta, S. Skrobot, and G. Luccarelli, “372 Ultrasonography and cytology in the follow up of grade 1 non-muscle invasive bladder cancer (NMIBC),” European Urology Supplements, vol. 12, no. 1, p. e372, 2013. View at Publisher · View at Google Scholar
  20. S. Gudjonsson, B. L. Isfoss, K. Hansson et al., “The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer,” European Urology, vol. 54, no. 2, pp. 402–408, 2008. View at Google Scholar
  21. P. M. J. Moonen, G. F. M. Merkx, P. Peelen, H. F. M. Karthaus, D. F. C. M. Smeets, and J. A. Witjes, “UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer,” European Urology, vol. 51, no. 5, pp. 1275–1280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Lodde, C. Mian, E. Comploj et al., “uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma,” Urology, vol. 67, no. 5, pp. 950–954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. N. P. Gupta, N. Sharma, and R. Kumar, “Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder,” Urology, vol. 73, no. 3, pp. 592–597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. T. Nguyen and J. S. Jones, “Defining the role of NMP22 in bladder cancer surveillance,” World Journal of Urology, vol. 26, no. 1, pp. 51–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Zellweger, G. Benz, G. Cathomas et al., “Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer,” International Journal of Cancer, vol. 119, no. 7, pp. 1660–1665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Kamat, J. A. Karam, H. B. Grossman, A. K. Kader, M. Munsell, and C. P. Dinney, “Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity,” BJU International, vol. 108, no. 7, pp. 1119–1123, 2011. View at Publisher · View at Google Scholar · View at Scopus